Monitoring patients with HIV disease

Journal of Clinical Pathology

Volumn 53, Issue 4, 2000, Pages 266-272

  Helbert, Matthew ^a   Breuer, Judy ^b  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; LYMPHOCYTE COUNT; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY CONTROL; REVIEW; VIRUS LOAD; VIRUS PATHOGENESIS;

ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CIRCADIAN RHYTHM; DRUG RESISTANCE, MICROBIAL; FLOW CYTOMETRY; HIV INFECTIONS; HUMANS; MONITORING, IMMUNOLOGIC; PREDICTIVE VALUE OF TESTS; VIRAL LOAD;

EID: 0034078854     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.53.4.266     Document Type: Review

References (80)

1. 1 Hoover DR. The effects of long term zidovudine therapy and Pneumocystis carinii prophylaxis on HIV disease. Drugs 1995;49:20-36.
2. 2 MMWR 97 1997. Revised guidelines for performing CD4 T cell determination in persons infected with human immunodeficiency virus. Morbidity and Mortality Monthly Report 1997;46:1-29.
3. 3 Barnett D, Bird G, Hodges E, et al. Guidelines for the enumeration of CD4 T lymphocytes in immunosuppressed individuals. Clin Lab Haematol 1997;19:231-41.
4. 4 British HIV Association. New British treatment guidelines, AIDS treatment update on line guidelines, 16.12.98; http://www.aidsmap.com
5. 5 Quillent C, Oberlin E, Braun J. HIV-1 resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet 1998;351:14-18.
6. 6 Daar ES, Moudgil T, Meyer RD, et al. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991;324: 961-4.
7. 7 Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68:4650-5.
8. 8 Phillips AN. Reduction of HIV concentration during acute infection: independence from a specific immune response. Science 1996;271:497-9.
9. 9 Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-8.
10. 10 Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
11. 11 Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
12. 12 Kati W, Johnson K, Jerva L, et al. Mechanism and fidelity of HIV reverse transcriptase. J Biol Chem 1992;267:25988-97.
13. 13 Boucher C, Lange JMA, Miedma F, et al. HIV 1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS 1992;6:1259-64.
14. 14 Sloan-Lancaster J, Evavold B, Allen P. Induction of T cell energy by altered T cell receptor ligand on live antigen presenting cells. Nature 1993;363:156-9.
15. 15 Tscherning C, Alaeus A, Fredriksson R. Difference in chemokine receptor usage between genetic subtypes of HIV-1. Virology 1998;241:181-8.
16. 16 Racz P, Tenner-Racz K, van-Vloten F, et al. Lymphatic tissue changes in AIDS and other retroviral infections: tools and insights. Lymphology 1990;23:85-91.
17. + T cells from human immunodeficiency virus infected asymptomatic individuals. J Exp Med 1992;175:331-40.
18. + T cells. Science 1992;257:383-7.
19. 19 Douek DC, McFarland RD, Gage EA, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998;396:690-4.
20. 20 Helbert MR, L'Age J, Mitchison NA. Is AIDS a consequence of abnormal antigen presentation? Immunol Today 1993;14:340-4.
21. 21 Havlir DV, Richman DD. The role of viral dynamics in the pathogenesis of HIV disease and implications for antiviral therapy. Springer Semin Immunopathol 1997;18:267-83.
22. 22 Nicholson JKA. Immunophenotyping specimens from HIV-infected persons: laboratory guidelines from the Centers for Disease Control and Prevention. Cytometry 1994;18: 55-9.
23. 23 Loken MR, Brosnan JM, Bach BA, et al. Quality control in flow cytometry: 1: establishing optimal lymphocyte gates for immunophenotyping by flow cytometry. Cytometry 1990;11:453-9.
24. 24 Nicholson JKA, Jones BM, Hubbard M. CD4 T-lymphocyte determinations on whole blood specimens using a single-tube three-color assay. Cytometry 1993;14:685-9.
25. 25 Ekong T, Kupek E, Hill A, et al. Technical influences on immunophenotyping by flow cytometry. The effect of time and temperature of storage on the viability of lymphocyte subsets. J Immunol Methods 1993;164:263-73.
26. 26 Ritchie AWS, Oswald I, Spedding Micklem H, et al. Circadian variation of lymphocyte subpopulations: a study with monoclonal antibodies. BMJ 1983;286:1773-5.
27. 27 Ullum H, Palmo J, Halkjaer-Kristensen J, et al. The effect of acute exercise on lymphocyte subsets, natural killer cells, proliferative responses, and cytokines in HIV-seropositive persons. J Acquir Immune Defic Syndr Hum Retrovirol 1994; 7:1122-33.
28. 28 Goodkin K, Feaster DJ, Asthana D, et al. A bereavement support group intervention is longitudinally associated with salutary effects on the CD4 cell count and number of physician visits. Clin Diagn Lab Immunol 1998;5:382-91.
29. 29 Maini MK, Gilson RJC, Chavda N, et al. Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. Genitourin Med 1996;72:27-31.
30. 30 Amasaki Y, Kobayashi S, Takeda T, et al. Upregulated expression of Fas antigen (CD95) by peripheral naïve and memory T cell subsets in patients with systemic lupus erythematosis (SLE); a possible mechanism for lymphopenia. Clin Exp Immunol 1995;99:245-50.
31. 31 Chailleux E, Bignon JD, Peyrat MA, et al. Lymphocyte subsets and phytohaemagglutinin responsiveness of blood lymphocytes, and interleukin 2 production in sarcoidosis. Thorax 1985;40:768-73.
32. 32 Jack AS, Richards S. CD4 cell counts used as surrogate test for HIV infection. BMJ;311:51-3.
33. 33 Masur H. Ognibene FP. Yarchoan R, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med 1989,111:223-31.
34. 34 Beck EJ, French PD, Helbert MR, et al. Improved outcome of Pneumocystis carinii pneumonia in AIDS patients; a multifactorial treatment effect. Int J STD AIDS 1992;3: 182-7.
35. 35 MMWR 97 1997. USPHS/IDSA Guidelines for the prevention of opportunist infections in persons infected with human immunodeficiency virus. Morbidity and Mortality Monthly Report 1997;46:1-46.
36. 36 Gibb D, ed. CD4 centile chart. Guidelines for management of children with HIV infection. AVERT-AIDS Education and Research Trust 1998;3:33.
37. 37 Valentine ME, Jackson CR, Vavro C, et al. Evaluation of surrogate markers and clinical outcomes in two-year follow-up of eighty-six human immunodeficiency virus-infected pediatric patients. Pediatr Infect Dis J 1998;17:18-23.
38. 38 MMWR 98. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Morbidity and Mortality Weekly Report 1998;47:1-31.
39. 39 European Collaborative Study Group. CD4 T cell count as predictor of Pneumocystis carinii pneumonia in children born to mothers infected with HIV. BMJ 1994;308:437-40.
40. 40 Helbert M. T cell receptor variable gene products and early HIV infection. Lancet 1992;339:1299.
41. 6 cells/1 following combination antiretroviral therapy including protease inhibitors. AIDS 1994;11: 1659-60.
42. 42 Jacobsen MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997;349:1443-5.
43. 43 Rose DN, Sacks HS. Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing. AIDS 1997;11:883-7.
44. 44 Bass HZ, Nishanian P, Hardy WD, et al. Immune changes in HIV 1 infection; significant correlations and differences in serum markers and lymphoid phenotypic analysis. Clin Immunol Immunopathol 1992;64:63-70.
45. + lymphocyte percent: a useful immunological marker for monitoring HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:158-62.
46. + T cells is a marker of poor prognosis in HIV infection: results of 6 years of follow-up. Cytometry 1996;26:1-7.
47. 47 Bass HZ, Hardy WD, Mitsuyasu RT, et al. Eleven lymphoid phenotypic markers in HIV infection; selective changes induced by zidovudine treatment. Journal of Acquired Immunodeficiency Syndrome 1992;5:890-7.
48. 48 Fahey JL, Taylor J, Detels R, et al. The prognostic value of cellular and serological markers in infection with human immunodeficiency virus. N Engl J Med 1993;322:166-72.
49. 49 Dunne J, Feighery C, Whelan A. Beta-2-microglobulin, neopterin and monocyte Fc gamma receptors in opportunistic infections of HIV-positive patients. Br J Biomed Sci 1996;53:263-9.
50. 50 Brew BJ, Dunbar N, Pemberton L, et al. Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of beta 2microglobulin and neopterin. J Infect Dis 1996;174:294-8.
51. 51 Mellors JW, Kingsley LA, Rinaldo CR, Jr, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-9.
52. 52 Mellors JW, Rinaldo CR, Jr, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
53. 53 Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
54. 54 Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nat Med 1996;2:625-9.
55. 55 Ginocchio CC, Wang XP, Kaplan MH, et al. Effects of specimen collection, processing, and storage conditions on stability of human immunodeficiency virus type 1 RNA levels in plasma. J Clin Microbiol 1997;35:2886-93.
56. 56 Rosok B, Voltersvik P, Bjerknes R, et al. Dynamics of HIV-1 replication following influenza vaccination of HIV+ individuals. Clin Exp Immunol 1996;104:203-7.
57. 57 Fowke KR, D'Arnico R, Chernorf DN, et al. Immunologic and virologic evaluation after influenza vaccination of HIV-1-infected patients. AIDS 1997;11:1013-21.
58. 58 Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 1996;157:1271-8.
59. 59 Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society - USA panel. JAMA 1998;280:78-86.
60. 60 Kempf DJ, Rode RA, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998;12:F9-14.
61. 61 Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 1998;338:853-60.
62. 62 Perrin L, Telenti A. HIV treatment failure: testing for HIV resistance in clinical practice. Science 1998;280:1871-3.
63. 63 Phillips AN, McLean A, Johnson MA, et al. HIV-1 dynamics after transient antiretroviral therapy: implications for pathogenesis and clinical management. Medical Virology 1997;53:261-5.
64. 64 Wong JK, Gunthard HF, Havlir DV, et al. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci U S A 1997;94:12574-9.
65. 65 Durant J, Clevenbergh P, Halfon P, et al. Drug-resistence genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999;353:2195-99.
66. 66 Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-5.
67. 67 Richman DD, Staszeweski S. A practical guide to HIV drug resistance and its implications for antiretroviral treatment strategies. London: International Medical Press, 1997.
68. 68 Shirasaka T, Kavlick MF, Ueno T, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci U S A 1995;92:2398-402.
69. 69 Condra JH, Holder DJ, Schleif WA, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996;70: 8270-6.
70. 70 Larder BA, Darby G, Richmann DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731-4.
71. 71 Japour AJ, Mayers DL, Johnson VA, et al. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1993;37:1095-101.
72. 72 Hertogs K, de Bethume MP, Miller V, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998;42:269-76.
73. 73 Miller V, Sturmer M, Staszewski S, et al. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors. AIDS 1998;12:705-12.
74. 74 Deeks SG, Smith M, Holodniy M, et al. HIV-1 protease inhibitors. A review for clinicians. JAMA 1997;277:145-53.
75. 75 Deeks SG, Abrams DI. Genotypic-resistance assays and antiretroviral therapy. Lancet 1997;349:1489-90.
76. 76 Brettle RP, Wilson A, Povey, et al. Combination therapy for HIV: the effect on inpatient activity, morbidity and mortality of a cohort of patients. Int J STD AIDS 1998;9: 80-7.
77. 77 Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. N Engl J Med 1999;340:1301-6.
78. 78 Burton AH, Mertens TE. Provisional country estimates of prevalent adult human immunodeficiency virus infections as of end 1994: a description of the methods. Int J Epidemiol 1998;27:101-7.
79. + T-cell quantitation for use in developing countries. AIDS 1993;7:1565-8.
80. 80 Zaknun D, DiFranco M, Oswald HP, et al. Association between neopterin and beta-2-microglobulin levels and HIV status in Romanian orphanage children. Wien Klin Wochenschr Suppl 1993;105:284-8.